A common solution to group 2 influenza virus neutralization

The discovery and characterization of broadly neutralizing antibodies (bnAbs) against influenza viruses have raised hopes for the development of monoclonal antibody (mAb)-based immunotherapy and the design of universal influenza vaccines. Only one human bnAb (CR8020) specifically recognizing group 2...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Friesen, Robert H. E., Lee, Peter S., Stoop, Esther J. M., Hoffman, Ryan M. B., Ekiert, Damian C., Bhabha, Gira, Yu, Wenli, Juraszek, Jarek, Koudstaal, Wouter, Jongeneelen, Mandy, Korse, Hans J. W. M., Ophorst, Carla, Brinkman-van der Linden, Els C. M., Throsby, Mark, Kwakkenbos, Mark J., Bakker, Arjen Q., Beaumont, Tim, Spits, Hergen, Kwaks, Ted, Vogels, Ronald, Ward, Andrew B., Goudsmit, Jaap, Wilson, Ian A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: National Academy of Sciences 2014
Soggetti:
Biological Sciences
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3890827/
https://ncbi.nlm.nih.gov/pubmed/24335589
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1319058110
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi